Highest-materiality recent filing
iBio reports single-dose IBIO-610 achieves 98% Activin E inhibition at 4 weeks in obese NHP study
Single dose of IBIO-610 reduced active Activin E by 98% at week 4 and 97% at week 8 vs baseline in obese NHPs.
iBio Q3: no revenue, cash $74.8M; Phase 1 clearance for IBIO-600; IBIO-610 reduces visceral fat 6.7%
No revenue for Q3 FY2026; R&D expenses $3.3M (up $1.4M YoY); G&A $5.1M (includes $2.5M impairment of IBIO-101 intangible).
Series G warrants expire at 5:00 p.m. ET on May 20, 2026 (30 trading days after public announcement).
iBio gets TGA/ethics approval for IBIO-600 Phase 1; warrants expire May 12
Received CTN acknowledgement from Australia's TGA and ethics committee approval to initiate first-in-human Phase 1 trial of IBIO-600.
Preclinical study: IBIO-610 reduced visceral fat by 6.7% and total fat mass by 5.2% after two doses every 8 weeks.
iBio enters $100M at-the-market equity agreement with Jefferies, terminates prior ATM
Entered Open Market Sale Agreement (ATM) with Jefferies LLC for up to $100M of common stock.
iBio reports Q2 FY2026 operating loss; secures $26M PIPE financing led by Frazier Life Sciences
No revenue for Q2 ended Dec 31, 2025, vs $0.2M a year ago; R&D expense $4.3M, G&A $5.2M (includes impairment of IBIO-101 intangible).
iBio raises $26M in PIPE led by Frazier Life Sciences to fund cardiometabolic programs
Gross proceeds of ~$26M from sale of 11.06M shares/pre-funded warrants at $2.35/share.
iBio Q1 FY2026 revenue $0.1M; cash $49.6M; IBIO-610 half-life up to 100 days
Revenue $0.1M vs $0 prior year; R&D expenses $3.6M (up $2.3M YoY); G&A $2.5M (down $0.3M).
iBio Reports Preclinical Data for IBIO-610 Showing Extended Half-Life in Obese Non-Human Primates
IBIO-610 half-life in obese NHP measured at 33.2 days.
iBio FY2025 revenue $0.4M, cash $8.8M; advances obesity pipeline with IBIO-610 fat loss data
Revenue $0.4M (up $0.2M YoY); R&D expense $8.3M (+$3.1M); G&A $10.7M (-$1.0M).
iBio prices $50M public offering of pre-funded warrants and Series G/H warrants
Combined offering price $0.699 per unit; gross proceeds ~$50M before underwriting discounts and expenses.
iBio updates corporate presentation; posts preliminary cash of $8.8M as of June 30, 2025
Preliminary cash of $8.8M as of June 30, 2025; audited FY2025 results expected later this quarter.
iBio receives Nasdaq deficiency notice for bid price below $1.00, has 180 days to cure
Received Nasdaq notice on July 29, 2025 for failing Minimum Bid Price of $1.00 for 30 consecutive business days.
iBio Q3 FY2025 net loss widens to $4.9M; pipeline progress with IBIO-600, Activin E
Net loss from continuing ops $4.9M ($0.49/share) vs $2.6M ($0.71/share) in Q3 FY2024.
iBio licenses first-in-class anti-Activin E antibody from AstralBio for up to $28M in milestones
Upfront $750K credit applied toward option fee; total milestone payments up to $28M, payable in cash or stock.
iBio reveals preclinical data for IBIO-600 and Activin E antibody combo with semaglutide
IBIO-600 NHP study: half-life 40-52 days, potential human half-life up to 130 days; dose-dependent lean mass increase and fat reduction.
IBIO-600 NHP half-life 40-52 days; estimated human half-life up to 130 days, enabling once every 3-6 month dosing.
iBio develops Activin E antibody for obesity; preclinical data shows sub-nanomolar binding
Antibody targeting Activin E for cardiometabolic disorders and obesity, developed with AstralBio Inc.
Upfront payment of $750,000 paid in common stock; milestones up to $28M.
iBio appoints David Arkowitz and António Parada as independent directors
David Arkowitz (Alkeus Pharma CFO) and António Parada (FairJourney Biologics CEO) join board effective Nov 25, 2024.
iBio FY2024 net loss $24.9M; revenue $0.2M; auditor raises going concern
Net loss narrowed to $24.9M from $65M YoY; R&D expense fell $5.1M, G&A fell $7.3M.
iBio sells Texas facility, eliminates $13.2M debt, completes AI biotech pivot
Sale of Bryan, TX manufacturing facility to Texas A&M Board of Regents for $8.5M cash.
iBio CDMO sells Texas A&M property for $8.5M; closing by May 31, 2024.
iBio Q3 net loss $2.6M; cash raised to $17.9M via PIPE; enters AstralBio collaboration
Net loss from continuing ops: $2.6M ($0.71/share) vs $6.3M ($9.53/share) YoY; no revenue.
iBio raises ~$15.1M in PIPE at $2.85/unit (148% premium), extends cash runway through FY2025
Gross proceeds of ~$15.1M from common shares, pre-funded warrants, and Series E warrants at $2.85 per unit.
iBio sells PD-1 agonist program to Otsuka for $1M upfront; up to $52.5M milestones
Otsuka acquired iBio's PD-1 agonist assets; $1M cash at closing, up to $52.5M in development and commercial milestones.
iBio replaces auditor CohnReznick with Grassi; prior audit included going concern note
Audit Committee approved Grassi & Co. as new auditor for FY ending June 30, 2024; engagement effective Feb 20, 2024.
Loan principal $1,071,572; net proceeds ~$1,027,455 after $42,863 origination fee.
iBio amends credit agreement: maturity extended to March 29, 2024, rate cut to 4.5%
Maturity extended from Dec 31, 2023 to earlier of March 29, 2024 or acceleration of term loan.
iBio effects 1-for-20 reverse stock split, reduces outstanding shares from 28.1M to 1.4M
Reverse stock split at 1:20 effective 12:01 a.m. ET Nov 29, 2023; shares continue trading as IBIO.
On May 7, 2026, Evert Schimmelpennink, a member of the Board, notified the Company of his decision to resign from the Board, including from his position as a member of the Compensation Committee of the Board, effective immediately.
On May 7, 2026, the Board of Directors (the “Board”) of iBio, Inc. (the “Company”), following the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Dr. Elizabeth Stoner, M.D., M.S., to serve as a Class II director of the Company, effective May 7, 2026
appointed Dr. Martin Brenner its then Interim Chief Executive Officer (CEO), to the position of permanent CEO effective immediately
and Mr. Felipe Duran, to the position of Interim Chief Financial Officer, effective as of February 13, 2023
appointed Dr. Martin Brenner to the position of Interim Chief Executive Officer, effective immediately
On January 11, 2023, Mr. Robert Lutz, the Chief Financial and Business Officer of iBio, Inc. (the “Company”) provided the Company notice of his resignation as an executive officer of the Company, effective February 10, 2023.
Mr. Thomas F. Isett, the Chief Executive Officer (the “CEO”) of iBio, Inc., (the “Company”) and a member of the Board of Directors (the “Board”), and the Company, agreed for Mr. Isett to resign as a member of the Board and relinquish his duties, rights and obligations as an officer and the CEO of the Company, effective immediately.
the Board approved the creation of the office of the Chief Executive Officer, whereby Mr. Robert Lutz, the Company's Chief Financial and Business Officer and Dr. Martin Brenner, the Company's Chief Scientific Officer will fill such role.
Mr. Isett resigned as CEO of the Company effective December 1, 2022
the Board approved the creation of the office of the Chief Executive Officer, whereby Mr. Robert Lutz, the Company's Chief Financial and Business Officer and Dr. Martin Brenner, the Company's Chief Scientific Officer will fill such role.
On November 1, 2022, Mr. Chip Clark was appointed as the Company’s Chairman of the Board.
On April 28, 2022, the Company received the resignation of Randy J. Maddux, its Chief Operating Officer, effective May 2, 2022.
Max materiality 0.85 · Median 0.60 · Most common event other_material